Predominantly, MR studies have already demonstrated the potential of radiomics for the prediction of molecular markers, such as the isocitrate dehydrogenase (IDH) genotype [15,16,17] or O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation [18,19,20], the assessment of prognosis in patients with newly diagnosed glioblastoma [21], and for the differentiation of radiation-induced changes predominantly after radiosurgery from local tumor relapse in patients with brain metastases [22,23,24]. The gene discussed is IDH3A; the disease is glioblastoma.